IMB Dx - Seoul, South Korea

IMB Dx is a precision oncology company that develops minimally-invasive liquid biopsy tests for safe & affordable cancer diagnosis and monitoring. Our liquid biopsy platform AlphaLiquid® is designed for early & advanced cancer patients for the purpose of accurate tumor profiling, therapy selection, recurrence monitoring, and early cancer detection.Our proprietary technology detects and analyzes trace amount of circulating tumor DNA (ctDNA) from a single draw of blood. We are committed to providing useful information for patients and physicians, and to revolutionize the way cancer is diagnosed, monitored, and treated.